Cancer-Loving Viruses & Antibodies Team Up Against Tumors

Matteus McCulloch from the University of Ottawa interviews Dr. Michele Ardolino, a senior scientist in cancer research at the Ottawa Hospital Research Institute and an Assistant Professor in the Department of Biochemistry, Microbiology and Immunology at the University of Ottawa. In this episode, Dr. Ardolino discusses a recent paper published by his lab about PD-L1 and its inhibition of the Type I IFN pathway during oncolytic virus infection, how the research came about, and the relevance of the work to advance cancer treatment. 

Learn more about Dr. Ardolino and the work of the Ardolino Lab:
https://www.uottawa.ca/faculty-medicine/dr-michele-ardolino
https://ardolinolab.ca/

0:00 | Introduction to PD-L1 and the type I IFN pathway and its relevance to recent research by Hodgins, J.J. et al.
1:40 | BEaTS, host, and guest introduction
2:18 | What inspired the Ardolino Lab's exploration of PD-L1 and the type I IFN pathway?
5:01 | What setbacks were encountered over the course of this study?
6:35 | What is the mechanism of action for PD-L1 antibodies and oncolytic viruses in cancer therapy?
8:17 | Clinical applications of PD-L1 antibodies and oncolytic viruses for cancer therapy
9:50 | Impactful moments during the research process
10:57 | Next steps in PD-L1 research
12:02 | Advice for students entering research
13:30 | End credits

This podcast features the following songs:
"Hidden Realm" by I.V.Lab, available under a Creative Commons Attribution-NonCommercial license.
Listen here: https://archive.org/details/ffs62
"600 light years" by Macroform, available under a Creative Commons Attribution-Noncommercial-Share Alike 3.0 license.
Listen here: https://archive.org/details/Macroform2011

Matteus McCulloch (Podcast Host), Serena Bezanson (Script Writer), Sara Ladha (Audio post-production), Mattheuren Aucoin (Producer).

Chapters

• 0:00 Introduction to PD-L1 and the type I IFN pathway, and its relevance to recent research by Hodgins, J.J. et. al.
• 1:40 BEaTS, host, and guest introduction
• 2:18 What inspired the Ardolino Lab's exploration of PD-L1 and the type I IFN pathway?
• 5:01 What setbacks were encountered over the course of this study?
• 6:35 What is the mechanism of action for PD-L1 antibodies and oncolytic viruses in cancer therapy?
• 8:17 Clinical applications of PD-L1 antibodies and oncolytic viruses for cancer therapy
• 9:50 Impactful moments during the research process
• 12:01 Advice for students entering research